From the American Academy of Ophthalmology

Using AREDS data, researchers compared progression rates within 4 natural genotype groups among patients with AMD who received placebo, antioxidants, zinc, or the AREDS formulation. The 4 groups were based on CFH and ARMS2 risk allele number. The authors found that only one group (AMD patients with no or 1 CFH risk allele and no ARMS2 risk allele) benefited from the AREDS formulation, which was neutral or unfavorable in the 3 other groups. The authors contend that the statistical relevance from studies that show no link between genetics and nutritional supplements is diminished by including too many variables. Ophthalmology, January 2015